The Impact of Semaglutide Compared to Energy Restriction on Type 2 Diabetes
Trial statusRecruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexAll
Age18-75
SponsorSecond Affiliated Hospital of Nanchang University
About this trial
To evaluate the effects of subcutaneous injection of semaglutide for 12 weeks on patients with type 2 diabetes mellitus (T2DM), compared with concurrent energy-restricted management, on glycemic control, weight loss, inflammatory markers, liver fat content, and other parameters. The study also observed the subcutaneous and visceral fat of the participants and explored the molecular mechanisms of action, providing high-quality evidence-based support for the timing and targets of intervention in this population.
Eligibility criteria
Qualifiers
Age 18-75 years;
BMI≥25 kg/m²;
Diagnosed as type 2 diabetes mellitus patients according to the "Guidelines for the Prevention and Treatment of Type 2 Diabetes in China (2020 Edition)";
HbA1c≤8.5%;
Disqualifiers
BMI < 25 kg/m²;
Age < 18 years, or > 75 years;
History of type 1 diabetes, acute pancreatitis, or diabetes secondary to pancreatectomy;
History of bariatric surgery or planned bariatric surgery, or currently attempting weight loss within the past 3 months, or use of weight-loss medications within the past 3 months;
Trial design
Treatments tested in this trial
- semaglutide
- caloric restriction
Treatment groups
100 Participants
are divided into 2 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov